

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Venrock Healthcare Capital Partners III, L.P.</u> (Last) (First) (Middle) C/O VENROCK 7 BRYANT PARK, 23RD FLOOR (Street) NEW YORK NY 10018 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>KalVista Pharmaceuticals, Inc. [KALV]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) 01/11/2024	
4. If Amendment, Date of Original Filed (Month/Day/Year)		
Rule 10b5-1(c) Transaction Indication <input type="checkbox"/> Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	01/11/2024		P		6,647	A	\$12.68 ⁽¹⁾	4,296,447 ⁽²⁾	I	By Funds ⁽³⁾
Common Stock	01/16/2024		P		19,599	A	\$12.73 ⁽⁴⁾	4,316,046 ⁽⁵⁾	I	By Funds ⁽³⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date					

1. Name and Address of Reporting Person*
Venrock Healthcare Capital Partners III, L.P.
 (Last) (First) (Middle)
 C/O VENROCK
 7 BRYANT PARK, 23RD FLOOR
 (Street)
 NEW YORK NY 10018
 (City) (State) (Zip)

1. Name and Address of Reporting Person*
VHCP Co-Investment Holdings III, LLC
 (Last) (First) (Middle)
 C/O VENROCK
 7 BRYANT PARK, 23RD FLOOR
 (Street)
 NEW YORK NY 10018
 (City) (State) (Zip)

1. Name and Address of Reporting Person*
VHCP Management III, LLC

(Last)	(First)	(Middle)
C/O VENROCK		
7 BRYANT PARK, 23RD FLOOR		
(Street)		
NEW YORK	NY	10018
(City)		
(State)	(Zip)	

1. Name and Address of Reporting Person*

[Venrock Healthcare Capital Partners EG, L.P.](#)

(Last)	(First)	(Middle)
C/O VENROCK		
7 BRYANT PARK, 23RD FLOOR		
(Street)		
NEW YORK	NY	10018
(City)		
(State)	(Zip)	

1. Name and Address of Reporting Person*

[VHCP Management EG, LLC](#)

(Last)	(First)	(Middle)
C/O VENROCK		
3340 HILLVIEW AVENUE		
(Street)		
PALO ALTO	CA	94304
(City)		
(State)	(Zip)	

1. Name and Address of Reporting Person*

[Koh Bong Y](#)

(Last)	(First)	(Middle)
C/O VENROCK		
7 BRYANT PARK, 23RD FLOOR		
(Street)		
NEW YORK	NY	10018
(City)		
(State)	(Zip)	

1. Name and Address of Reporting Person*

[Shah Nimish P](#)

(Last)	(First)	(Middle)
C/O VENROCK		
7 BRYANT PARK, 23RD FLOOR		
(Street)		
NEW YORK	NY	10018
(City)		
(State)	(Zip)	

Explanation of Responses:

- The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from \$12.55 to \$12.75 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
- Consists of (i) 944,499 shares held by Venrock Healthcare Capital Partners III, L.P. ("VHCP3"); (ii) 94,484 shares held by VHCP Co-Investment Holdings III, LLC ("VHCP Co-3"); and (iii) 3,257,464 shares held by Venrock Healthcare Capital Partners EG, L.P. ("VHCP EG").
- VHCP Management III, LLC ("VHCPM3") is the general partner of VHCP3 and the manager of VHCP Co-3 and may be deemed to beneficially own these shares. VHCP Management EG, LLC ("VHCPMEG") is the general partner of VHCP EG and may be deemed to beneficially own these shares. Bong Koh and Nimish Shah are the voting members of VHCPM3 and VHCPMEG and may be deemed to beneficially own these shares. Each of VHCPM3, VHCPMEG and Messrs. Koh and Shah expressly disclaims beneficial ownership over these shares except to the extent of its or his indirect pecuniary interest therein.
- The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from \$12.59 to \$12.75 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
- Consists of (i) 949,652 shares held by VHCP3; (ii) 94,999 shares held by VHCP Co-3; and (iii) 3,271,395 shares held by VHCP EG.

Remarks:

[Management III, LLC, Its:](#)
[General Partner, By: /s/](#)
[Sherman G. Souther,](#)
[Authorized Signatory.](#)
[VHCP Co-Investment](#)
[Holdings III, LLC, By: VHCP](#)
[Management III, LLC, Its:](#) 01/16/2024
[Manager, By: /s/ Sherman G.](#)
[Souther, Authorized Signatory.](#)
[VHCP Management III, LLC,](#)
[By: /s/ Sherman G. Souther,](#) 01/16/2024
[Authorized Signatory.](#)
[Yenrock Healthcare Capital](#)
[Partners EG, L.P., By: VHCP](#)
[Management EG, LLC, Its:](#) 01/16/2024
[General Partner, By: /s/](#)
[Sherman G. Souther,](#)
[Authorized Signatory.](#)
[VHCP Management EG, LLC,](#)
[By: /s/ Sherman G. Souther,](#) 01/16/2024
[Authorized Signatory.](#)
[Bong Koh, By: /s/ Sherman G.](#) 01/16/2024
[Souther, Attorney-in-fact](#)
[Nimish Shah, By: /s/ Sherman](#) 01/16/2024
[G. Souther, Attorney-in-fact](#)

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.